ESR1 Gene Polymorphisms and Prostate Cancer Risk: A HuGE Review and Meta-Analysis

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wang, Yu Mei ^a   Liu, Zu Wang ^a   Guo, Jing Bo ^a   Wang, Xiao Fang ^a   Zhao, Xin Xin ^a   Zheng, Xuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASIAN; CANCER RISK; CASE CONTROL STUDY; CAUCASIAN; CODON; ESR1 GENE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INDIAN; NUCLEIC ACID BASE SUBSTITUTION; POPULATION RISK; PROSTATE CANCER; SYSTEMATIC REVIEW; XBAL GENE; FACTUAL DATABASE; GENETIC PREDISPOSITION; GENETICS; MALE; META ANALYSIS; ODDS RATIO; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN;

CASE-CONTROL STUDIES; DATABASES, FACTUAL; ESTROGEN RECEPTOR ALPHA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84879270218     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066999     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Becker N, (2011) Epidemiology of prostate cancer. Radiologe 51: 922-929.
3. Zhao ZY, San M, Duprey JL, Arrand JR, Vyle JS, et al. (2012) Detection of single nucleotide polymorphisms within a sequence of a gene associated with prostate cancer using a fluorophore-tagged DNA probe. Bioorg Med Chem Lett 22: 129-132.
4. Onsory K, Sobti RC, Al-Badran AI, Watanabe M, Shiraishi T, et al. (2008) Hormone receptor-related gene polymorphisms and prostate cancer risk in North Indian population. Mol Cell Biochem 314: 25-35.
5. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, et al. (2010) Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev 19: 1871-1878.
6. Low YL, Taylor JI, Grace PB, Mulligan AA, Welch AA, et al. (2006) Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer 56: 31-39.
7. Sivonova MK, Dobrota D, Dusenka R, Waczulikova I, Slezak P, et al. (2012) Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population. Mol Biol Rep 39: 7871-7880.
8. Wang F, Zou YF, Feng XL, Su H, Huang F, (2011) CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies. Prostate 71: 1167-1177.
9. Lee KM, Kang D, Park SK, Berndt SI, Reding D, et al. (2009) Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 30: 621-625.
10. Wang LZ, Sato K, Tsuchiya N, Yu JG, Ohyama C, et al. (2003) Polymorphisms in prostate-specific antigen (PSA) gene, risk of prostate cancer, and serum PSA levels in Japanese population. Cancer Lett 202: 53-59.
11. Li LC, Shiina H, Deguchi M, Zhao H, Okino ST, et al. (2004) Age-dependent methylation of ESR1 gene in prostate cancer. Biochem Biophys Res Commun 321: 455-461.
12. McIntyre MH, Kantoff PW, Stampfer MJ, Mucci LA, Parslow D, et al. (2007) Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev 16: 2233-2236.
13. Cowley SM, Hoare S, Mosselman S, Parker MG, (1997) Estrogen receptors alpha and beta form heterodimers on DNA. J Biol Chem 272: 19858-19862.
14. Chae YK, Huang HY, Strickland P, Hoffman SC, Helzlsouer K, (2009) Genetic polymorphisms of estrogen receptors alpha and beta and the risk of developing prostate cancer. PLoS One 4: e6523.
15. Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, et al. (2008) Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 102: 442-445.
16. Safarinejad MR, Safarinejad S, Shafiei N (2012) Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: Evidence for association with risk and histopathological tumor characteristics in Iranian men. Mol Carcinog.
17. Nelles JL, Hu WY, Prins GS, (2011) Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 6: 437-451.
18. da Costa BR, Cevallos M, Altman DG, Rutjes AW, Egger M, (2011) Uses and misuses of the STROBE statement: bibliographic study. BMJ Open 1: e000048.
19. Stang A, (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25: 603-605.
20. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
21. Zintzaras E, Ioannidis JP, (2005) Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137.
22. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680.
23. Cancel-Tassin G, Latil A, Rousseau F, Mangin P, Bottius E, et al. (2003) Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. Eur Urol 44: 487-490.
24. Fukatsu T, Hirokawa Y, Araki T, Hioki T, Murata T, et al. (2004) Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 24: 2431-2437.
25. Gupta L, Thakur H, Sobti RC, Seth A, Singh SK, (2010) Role of genetic polymorphism of estrogen receptor-alpha gene and risk of prostate cancer in north Indian population. Mol Cell Biochem 335: 255-261.
26. Hernandez J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, et al. (2006) Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men. J Urol 175: 523-527.
27. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, et al. (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7: 3092-3096.
28. Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, et al. (2011) Estrogen receptor alpha and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy. J Clin Endocrinol Metab 96: E368-372.
29. Sobti RC, Gupta L, Singh SK, Seth A, Kaur P, et al. (2008) Role of hormonal genes and risk of prostate cancer: gene-gene interactions in a North Indian population. Cancer Genet Cytogenet 185: 78-85.
30. Sonoda T, Suzuki H, Mori M, Tsukamoto T, Yokomizo A, et al. (2010) Polymorphisms in estrogen related genes may modify the protective effect of isoflavones against prostate cancer risk in Japanese men. Eur J Cancer Prev 19: 131-137.
31. Suzuki K, Matsui H, Nakazato H, Koike H, Okugi H, et al. (2003) Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett 195: 177-183.
32. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, et al. (2003) Polymorphisms of estrogen receptor alpha in prostate cancer. Mol Carcinog 37: 202-208.
33. Bonkhoff H, Berges R, (2009) The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol 55: 533-542.
34. Dutt SS, Gao AC, (2009) Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 5: 1403-1413.
35. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, et al. (2008) Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 22: 1512-1520.
36. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, et al. (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 969-978.
37. Nicolaiew N, Cancel-Tassin G, Azzouzi AR, Grand BL, Mangin P, et al. (2009) Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol 160: 101-106.
38. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, et al. (2001) Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol 159: 79-92.
39. Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, et al. (2001) Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 168: 447-454.
40. Risbridger GP, Wang H, Frydenberg M, Cunha G, (2001) The metaplastic effects of estrogen on mouse prostate epithelium: proliferation of cells with basal cell phenotype. Endocrinology 142: 2443-2450.
41. Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, et al. (2006) Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 12: 2545-2554.
42. Imamov O, Shim GJ, Warner M, Gustafsson JA, (2005) Estrogen receptor beta in health and disease. Biol Reprod 73: 866-871.
43. Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Gronholdt ML, et al. (2007) Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case-control studies and a meta-analysis. Circulation 115: 861-871.
44. Shibata A, Whittemore AS, (1997) Genetic predisposition to prostate cancer: possible explanations for ethnic differences in risk. Prostate 32: 65-72.